Gut Bacteria Phenotype to Biomarker/Therapeutics

Microbiotica is focused on developing precision microbiome medicines through its innovative platform that leverages clinic-led microbiome science. The company is advancing a pipeline of defined live biotherapeutic products (LBPs) that are designed for oral delivery and target specific therapeutic applications, particularly in immuno-oncology and inflammatory bowel disease. By utilizing a discovery platform that enables the precise identification of bacterial strains linked to patient outcomes, Microbiotica aims to tailor treatments to specific patient populations, enhancing the efficacy of its therapies.

The company's approach is characterized by its commitment to translating scientific research into clinical applications, with a strong emphasis on known mechanisms of action for its products. Microbiotica's pipeline includes several clinical trials, such as the Phase 1b trials for its products MB310 and MB097, which are aimed at treating ulcerative colitis and advanced melanoma, respectively. This focus on clinic-ready products underscores Microbiotica's goal of delivering transformative, life-changing medicines that are grounded in robust scientific evidence.

United Kingdom

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers

Microbiotica

Company Details